Literature DB >> 27191176

Graft-versus-host Disease-associated Angiomatosis Treated With Topical Timolol Solution.

Benjamin R Bashline1, Michael Mortazie1, Brian Schapiro2, David Fivenson1.   

Abstract

INTRODUCTION: Scleroderma-like graft-versus-host disease (GVHD) is an uncommon subtype of chronic GVHD. Vascular lesions rarely arise within areas of scleroderma-like changes and until recent- ly have not been considered to be related entities. Kaffenberg et al1 have grouped this heterogeneous collection of vascular lesions under the term GVHD-associated angiomatosis. Treatment modalities thus far have been mostly ineffective. Topical timolol solution has been used in the treatment of superficial infantile hemangiomas with good success. Here the authors report the first case of GVHD-associated angiomatosis treated with topical timolol solution. METHODS AND MATERIALS: Timolol 0.5% solution was applied daily to 3 lesions on the lower extremities of their patient for 3 months.
RESULTS: All lesions decreased in friability and frequency of spontaneous hemorrhage. Le- sions remained stable in size throughout treatment duration, with no growth observed in any lesion. Granulation tissue surrounding all lesions was markedly reduced after the treatment period.
CONCLUSION: Topical timolol remains a promising therapeutic option in the treat- ment of GVHD-associated angiomatosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27191176

Source DB:  PubMed          Journal:  Wounds        ISSN: 1044-7946            Impact factor:   1.546


  2 in total

1.  Angiolymphoid Hyperplasia with Eosinophilia and its Response to the Combination of Radiofrequency Ablation and Topical Timolol.

Authors:  Pooja Arora; Neha Meena; Prafulla K Sharma; Minakshi Bhardwaj
Journal:  Indian Dermatol Online J       Date:  2017 Jul-Aug

Review 2.  Topical beta-blockers in dermatologic therapy.

Authors:  Angela Filoni; Francesca Ambrogio; Aurora De Marco; Alessia Pacifico; Domenico Bonamonte
Journal:  Dermatol Ther       Date:  2021-06-21       Impact factor: 2.851

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.